Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;14(3):2541-7.
doi: 10.3892/mmr.2016.5536. Epub 2016 Jul 21.

Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population

Affiliations

Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population

Ying-Yu Ma et al. Mol Med Rep. 2016 Sep.

Abstract

The coxsackie and adenovirus receptor (CAR) is considered a tumor suppressor and critical factor for the efficacy of therapeutic strategies that employ the adenovirus. However, data on CAR expression levels in colorectal cancer are conflicting and its clinical relevance remains to be elucidated. Immunohistochemistry was performed on tissue microarrays containing 251 pairs of colon cancer and adjacent normal tissue samples from Chinese Han patients to assess the expression levels of CAR. Compared with healthy mucosa, decreased CAR expression (40.6% vs. 95.6%; P<0.001) was observed in colorectal cancer samples. The CAR immunopositivity in tumor tissues was not significantly associated with gender, age, tumor size, differentiation, TNM stage, lymph node metastasis or distant metastasis in patients with colon cancer. However, expression of CAR is present in 83.3% of the tumor tissues from patient with colorectal liver metastasis, which was significantly higher than those without liver metastasis (39.6%; P=0.042). At the plasma membrane, CAR was observed in 29.5% normal mucosa samples, which was significantly higher than in colorectal cancer samples (4.0%; P<0.001). In addition, the survival analysis demonstrated that the expression level of CAR has no association with the prognosis of colorectal cancer. CAR expression was observed to be downregulated in colorectal cancer, and it exerts complex effects during colorectal carcinogenesis, potentially depending on the stage of the cancer development and progression. High CAR expression may promote liver metastasis. With regard to oncolytic therapy, CAR expression analysis should be performed prior to adenoviral oncolytic treatment to stratify Chinese Han patients for treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemical analysis of CAR in colon cancer and normal tissue. (A) Immunostaining of CAR in normal colon tissue, positive staining was observed in the cytoplasm and, predominantly, the membrane. (B) Immunostaining of CAR in poorly differentiated colon cancer, positive staining was predominantly observed in the cytoplasm. (C) Immunostaining of CAR in moderately differentiated colon cancer, positive staining was observed in the membrane and, predominantly, the cytoplasm. (D) Immunostaining of CAR in colon cancer with liver matastasis, positive staining was observed in the cytoplasm and membrane. Magnification, ×400. CAR, coxsackie and adenovirus receptor.
Figure 2
Figure 2
Kaplan-Meier survival curve analysis in patients with positive and negative CAR expression demonstrating CAR expression has no significant association with overall survival. CAR, coxsackie and adenovirus receptor.

Similar articles

Cited by

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21. - PMC - PubMed
    1. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD, Standards Practice Task Force of the American Society of Colon and Rectal Surgeons Practice parameters for the management of colon cancer. Dis Colon Rectum. 2012;55:831–843. doi: 10.1097/DCR.0b013e3182567e13. - DOI - PubMed
    1. Rayburn ER, Wang W, Zhang R, Wang H. Experimental therapy for colon cancer: Anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol. 2007;30:1511–1519. - PubMed
    1. Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: Current questions. Cancer. 2008;112:1879–1891. doi: 10.1002/cncr.23409. - DOI - PubMed

MeSH terms

Substances